The drug bank data needs to be examined and solutions developed for the extraction of meaningful terms and data regarding indications to help with the AMP/ASCO Tiering evaluation.
Values:
Cancer type (ex. Non-Small Cell Lung Cancer or Microsatellite Instability-High Cancer)
Biomarker, not all indications will have this (ex. Non-Small Cell Lung Cancer (NSCLC); in combination with [pemetrexed] and platinum-based chemotherapy as a first-line treatment for patients with metastatic nonsquamous NSCLC with no EGFR or ALK mutations)
Combination drug (ex. "in combination with carboplatin and paclitaxel as a first-line treatment for patients with metastatic squamous NSCLC")
The drug bank data needs to be examined and solutions developed for the extraction of meaningful terms and data regarding indications to help with the AMP/ASCO Tiering evaluation.
Values: Cancer type (ex. Non-Small Cell Lung Cancer or Microsatellite Instability-High Cancer)
Biomarker, not all indications will have this (ex. Non-Small Cell Lung Cancer (NSCLC); in combination with [pemetrexed] and platinum-based chemotherapy as a first-line treatment for patients with metastatic nonsquamous NSCLC with no EGFR or ALK mutations)
Combination drug (ex. "in combination with carboplatin and paclitaxel as a first-line treatment for patients with metastatic squamous NSCLC")